LAKE OSWEGO, Ore., May 8, 2017 /PRNewswire/ -- BIOTRONIK today announced FDA approval of the company's MultiPole Pacing (MPP) technology, providing physicians with additional treatment options for heart failure patients who have been non-responsive to cardiac resynchronization therapy (CRT).1 MPP will be available on new BIOTRONIK CRT defibrillator (CRT-D) systems for patients with heart failure.
Nearly 40 percent of heart failure patients are initially non-responsive to CRT.2 BIOTRONIK's innovative MPP technology addresses this challenge by enabling the left ventricle to be paced twice per cardiac cycle. Uniquely, these paces can be either sequential or simultaneous, allowing for greater customization of therapy to meet specific patient needs. BIOTRONIK CRT-D systems include MPP and feature ProMRI® technology, providing patients with access to critical diagnostic imaging scans as needed. These devices are also equipped with MRI AutoDetect, a dedicated sensor that detects the MRI environment, converts the patient's device to MRI mode, and then automatically returns to its permanent program when the scan is complete.
BIOTRONIK’s innovative MPP technology allows for greater customization of therapy to meet specific heart failure patient needs.
Ad Statistics
Times Displayed: 656
Times Visited: 5 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
BIOTRONIK’s innovative MPP technology allows for greater customization of therapy to meet specific heart failure patient needs.
With the availability of MPP, BIOTRONIK now offers the most comprehensive MR conditional CRT portfolio available today to ensure physicians have access to the best possible cardiac rhythm management solution.
"MultiPole Pacing is an important technology that allows physicians to tailor cardiac resynchronization therapy to each patient," said Dr. Gery Tomassoni, Baptist Health, Lexington, Kentucky. "Heart failure is a complex condition and physicians are routinely challenged to find the ideal treatment for unique disease presentations. Adding MPP technology to other key BIOTRONIK features creates more options for physicians to meet evolving patient needs."
"When we develop technologies and evolve our devices, we think first and foremost about patients. Patients deserve the best care possible and innovation that truly enhances everyday life," said Marlou Janssen, President of BIOTRONIK, Inc. "Patients with heart failure are the most complex to treat, and they often have additional comorbidities that are likely to change and worsen over time. BIOTRONIK rises to this challenge by continuing to innovate, and offering impactful, customizable solutions to physicians that meet the ever-changing landscape of patients' needs."
